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Abstract 
The fifth “Melanoma Bridge Meeting” took place in Naples, December 1–5th, 2015. The main topics discussed at this 
meeting were: Molecular and Immuno advances, Immunotherapies and Combination Therapies, Tumor Microenviron-
ment and Biomarkers and Immunoscore. The natural history of cancer involves interactions between the tumor and 
the immune system of the host. The immune infiltration at the tumor site may be indicative of host response. Signifi-
cant correlations were shown between the levels of immune cell infiltration in tumors and patient’s clinical outcome. 
Moreover, incredible progress comes from the discovery of mutation-encoded tumor neoantigens. In fact, as tumors 
grow, they acquire mutations that are able to influence the response of patients to immune checkpoint inhibitors. It 
has been demonstrated that sensitivity to PD-1 and CTLA-4 blockade in patients with advanced NSCLC and mela-
noma was enhanced in tumors enriched for clonal neoantigens. The road ahead is still very long, but the knowledge 
of the mechanisms of immune escape, the study of tumor neo-antigens as well as of tumor microenvironment and 
the development of new immunotherapy strategies, will make cancer a more and more treatable disease.
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Background
Because cancer is a heterogeneous and dynamic micro-
environment communicating with the immune system, 
the immune contexture of tumor microenvironment 
showed to be able influence the course of the disease. 
Hence, pre-existing immunity is determining the fate and 
survival of the patient and the likelihood of response to 
immunotherapy.
Quantification of immune cell densities (n  =  415 
patients, 6640 immunostains) revealed the major positive 
role of cytotoxic and memory T cells for patient’s survival 
[1]. These findings became the foundation of a new con-
cept: immune contexture (i.e. nature, functional orienta-
tion, density, and location within distinct tumor regions, 
of a natural in  situ immune reaction) might be used by 
immunoscore. Recently, many reports suggest that can-
cer development is controlled by the host’s immune 
system underlying the importance of including immu-
nological biomarkers for the prediction of prognosis and 
response to therapy. For this reason, the impact of the 
immunoscore needs to be evaluated more thoroughly in 
other tumor types given the universal importance of the 
immune system in cancers.
Update on Immunoscore Worldwide Consortium 
(SITC) and Immunoscore on other cancer types
Immunoscore in colorectal cancer
The Immunoscore is now defined as a prognostic tool 
to use for quantification of in  situ immune cell infil-
trates, which appears to be superior to the tumor-node-
metastasis (TNM) classification in colorectal cancer. 
In NSCLC, no Immunoscore has been established, but 
in situ tumor immunology is recognized as highly impor-
tant [2]. The question still open is the challenge of the 
“universal” character of the Immunoscore.
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In 2006 it was demonstrated that the immunologi-
cal data (the type, density, and location of immune cells 
within the tumor samples) are a better predictor of 
patient survival than the histopathological methods cur-
rently used to stage colorectal cancer. An international 
consortium has been initiated to validate and promote 
the Immunoscore in routine clinical settings [3]. Specifi-
cally, an Immunoscore based on the combined analysis 
of CD8+ plus CD45RO+ cells in specific tumor regions 
was a useful criterion for the prediction of tumor recur-
rence and survival in patients with early-stage (AJCC/
UICC-TNM stages I and II) CRC. Also, when consid-
ering the disease-specific survival according to CD8+ 
and CD45RO+ densities in combined tumor regions 
(central tumor/invasive margin, CT/IM), the scoring 
system allows to identify subgroups of patients with dis-
tinct clinical outcomes in terms of disease-free survival 
and overall survival [4]. The importance of the localized 
immune reaction in predicting recurrence and survival 
in patients with early-stage colorectal carcinoma has also 
been assessed [5].
The Immunoscore in colorectal cancer highlights the 
importance of digital scoring systems in surgical pathol-
ogy. More specifically, in rectal cancers the evaluation 
of the impact of the immune infiltrate on prognosis in 
patients treated by primary surgery seemed to show sig-
nificant differences between patient groups for survival 
times, with the poorest postoperative outcome in those 
with low densities of CD3 and CD8 in both central tumor 
and invasive margins [6]. It was also demonstrated that 
pre-existing CD8+ T cells distinctly located at the IM are 
associated with expression of the PD-1/PD-L1 immune 
inhibitory axis and may predict response to therapy [7]. 
In patients with refractory Hodgkin’s lymphoma treated 
with an anti PD-1 antibody (nivolumab) the objective 
response rate was 87 % [8].
The Immunoscore validation study aims at standard-
izing the procedures among centers through the provi-
sion of (a) recommendations for the IHC (CD3 & CD8) 
(b) a manual for the use of the software and (c) a tutorial 
to illustrate the drawing of the tumor regions in terms of 
heterogeneity (which clones of antibodies, staining auto-
mation and protocol, scanner used) and of non-heteroge-
neity (“Immunoscore module” of the software). The final 
results should be able to illustrate the robustness of the 
test.
Recently, Bern, Erlangen and Prague organized in a 
consortium now including data from more than 1000 
CRC patients. Every site had to run through a digital 
workflow with tumor and stroma annotation, followed 
by detection of the invasive margin and automated quan-
tification of the immune cells with CD3 and CD8 stain-
ing. The turn-around time of the whole digital analysis 
procedure has been estimated in 15  h, which seems 
reasonable also for clinical decision processes. Another 
point is how the digital analysis fits into the highly 
standardized pathology workflows existing in the clin-
ics. The Immunoscore has the noteworthy advantage of 
being very close to routine pathology. The pathologist 
is engaged three times (blocking selection, marking the 
tumor area, that is time consuming and needs a special 
training, and reporting), still it is worth to integrate the 
Immunoscore owing to its capability to reflect the status 
of tumor infiltrating lymphocytes in the center and in 
the invasive margin. Patients were previously grouped by 
cut-offs for Kaplan Meyer curve calculation, losing valu-
able quantitative information. To overcome these two 
limitations, a more advanced software solution, which is 
faster, including an automatic detection of the tumor, and 
keeping the quantitative density values combined into a 
score, should be developed. It might be also overcome by 
reporting results in a scale format to enable clinicians to 
make a decision integrating the combination of markers 
and balancing the risks. This is feasible for the Immu-
noscore [9].
The Hôpital Européen Georges Pompidou of Paris, 
France (HEGP) developed an Immunomonitoring Plat-
form in order to perform a quality control check at the 
initiation and at the end of the study. At the beginning 
of the study, adjacent slides were compared in the IHC 
in order to evaluate the quality and intensity of the stain-
ing. This permitted to create a tool to check the staining 
intensity. At the end of the study, all the immunostain-
ings of each center were checked on the selection of the 
tumor region of interest, on the quality and intensities of 
the staining and on the detection of the stained cells.
As a prognostic tool in other cancers, high densities of 
CD3+ T cells, CD8+ cytotoxic T cells and CD45RO+ 
memory T cells are associated with a longer disease-free 
survival (after surgical resection of the primary tumor) 
and/or overall survival [10].
The Worldwide Immunoscore Consortium is system-
atically studying the Immunoscore as a new possible 
approach for the classification of cancer with the involve-
ment of 23 centers, 17 Countries and more than 3000 
patients. Three cohorts of colon cancer patients consist-
ing into a training set, an internal validation set and an 
external validation set will be analyzed with a pre-defined 
analysis work plan by an external statistician, independ-
ent of the consortium. In other studies, the impact of 
Immunoscore on several types of cancer is being evalu-
ated. A quantitative analysis of tumor-infiltrating lym-
phocytes (TILs) subsets within brain metastasis, coming 
from multiple primary tumors (mainly melanoma, breast, 
kidney, lung cancer), was performed and the prognostic 
impact of Immunoscore was evaluated. Immunoscore 
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showed significant correlation with survival prognosis 
[11]. Furthermore, more prospective studies implement-
ing the Immunoscore (as the one reported by Anitei 
et  al.) [6] are yet needed in order to convert it from a 
prognostic tool into a predictive one.
Immunoscore in melanoma
Immune-regulated pathways influence multiple aspects 
of tumor development and present multiple opportu-
nities to gage its response in order to make treatment 
decisions regarding: (1) prognosis (the presence of the 
right immune effector cells is correlated with better 
prognosis and survival) (2) immunotherapy (manipu-
late the patient’s own immune system to respond to the 
tumor) and (3) chemotherapy (response may also be 
immune-related).
The definition of Immunoscore in melanoma, based on 
the complex intratumoral immune reaction, is becoming 
a difficult challenge. So far the value of the Immunoscore 
has been well established in patients with early-stage 
(stage I–II) colorectal cancer where the immune profile 
seems have higher prognostic importance than clinical 
features such as TNM-staging system [5].
The Immunoscore is evaluated in metastatic lymph 
node tissue because they represent an extremely inter-
esting model for a number of reasons as it has jet been 
demonstrated: for adjuvant therapy (melanoma stage III), 
they are more accessible than visceral metastases and the 
risk for distant metastases is high, and at last [12–14]. 
Patients with a stage III disease can benefit from an adju-
vant therapy (interferon, immunotherapy), in fact, the 
evaluation of the microenvironment in the lymph nodes 
could be important for patient selection, and In many 
cases, the metastatic lymph nodes from lymphectomy are 
the only available tissue.
On the other hand, concerns are raised about the 
Immunoscore in lymph nodes because they are constitu-
tively rich in CD3 and CD20 lymphocytes and, also, the 
evaluation of the periphery of the tumor is particularly 
complex. Moreover, lymph node metastases may be dif-
ferent in terms of immune infiltration compared to other 
metastatic lesions. Clinical outcome and prognostic fac-
tors of superficial and deep lymph node dissection for 
stage III cutaneous melanoma were retrospectively stud-
ied in patients who underwent surgical lymph node dis-
section for metastases at the National Cancer Institute, 
Naples. One of the aims was to develop an algorithm for 
the evaluation of the different markers [15]. In the cell 
counts for each patient, no apparent differences were 
found in expression levels in the reactive lymph nodes 
between relapse and no relapse groups, except for CD8, 
in which there were more patients with high express-
ing cells in the relapse group. There were significant 
differences in the peri/intra ratio for both CD3 and CD8, 
with the ratio being higher in no relapse patients com-
pared to relapse patients for both proteins. Similar differ-
ences were seen in FoxP3 and CD20. These preliminary 
data were used to develop a risk score currently investi-
gated in a larger melanoma cohort. The algorithm was 
developed using the whole slide images from serial sec-
tions stained with different markers that were automati-
cally identified from tumor marker slide. Region labels 
were then transferred to marker slides via image registra-
tion and cells were automatically counted for each region. 
The report of cell counts and region labels for each 
patient was analyzed in the onco-immune report [16].
In order to investigate the predictive power of Immu-
noscore, the MISIPI study has involved 200 FPFE samples 
from metastatic melanoma patients treated with Ipili-
mumab where density of different immune populations 
was assessed, using a digital image analysis application to 
characterize immune infiltrate expression of CD3, CD8, 
CD20, FoxP3 and CD163 and of PD-L1. The aim was 
to correlate marker expression profile with clinical out-
come [17]. No relationship between CD3, CD8, CD20, 
CD163, FoxP3 both intratumoral (CT) and peritumoral 
(IM) with response/benefit was evidenced, but only a 
trend for the CD163 positive PD-L1 positive (CT) popu-
lation (p =  0.07). CD8+ PD-L1− and higher and lower 
than median at IM seems to correlate with OS (p = 0.04). 
A similar correlation was found for CD163+ PD-L1+ 
(p = 0.05). The conjugated analysis presented even better 
correlation with overall survival (OS) (p = 0.01).
In the same time, a proof-of-concept study was 
designed with 31 patients (11 CR, 1 PR, 4 SD and 15 
PD) on first line treatment with cisplatin  +  temodal 
or dacarbazine or other. Tissue sections were stained 
with H&E, CD3 and FoxP3. Co-expression analysis was 
performed on the basis of an automated alignment of 
serial sections in order to correlate cell density patterns 
with Ipilimumab patient OS. First results indicate that 
melanocyte-FoxP3 spatial relations are the most predic-
tive factors and that, while CD3 alone does not provide 
substantial value, CD3/FoxP3 ratio on IM seems to be a 
promising additional factor.
Immunoprofiling (next generation)
The success of immunotherapy for the treatment of met-
astatic melanoma is contingent on the identification of 
appropriate target antigens. As immunotherapy strate-
gies become increasingly sophisticated and powerful, 
finding new biomarkers whose expression is predictive 
of the efficacy of immunotherapy is a major challenge to 
maximize patient tremendous growth in the understand-
ing of the immune response to cancer is beginning to 
generate breakthroughs in cancer treatment. However, 
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our understanding of immuno-oncology is far from com-
plete. There is a need to explore the complex relation-
ship between the immune system and primary tumors, 
in both the tumor microenvironment and in peripheral 
blood, as well as to robustly monitor changes in the 
immune response associated with potential therapeutic 
approaches.
It has been demonstrated that PD1–PDL1 blockade 
efficacy requires pre-existing adaptive immune resistance 
[7, 18]. In order to objectively determine PD-L1 protein 
levels, FDA approved 4 different companion diagnostic 
immunohistochemistry (IHC) tests for PD-L1 in NSCLC. 
However, both heterogeneity within tumors and promi-
nent inter-assay variability or discordance has been found 
[19]. Two programs were started in order to improve the 
understanding of PD-L1 protein expression in lung can-
cer: “Rx/Dx Industry PD-L1 Blueprint Proposal” of FDA-
AACR-ASCO and the “Multi-Institutional Analysis of 
Programmed Cell Death-Ligand 1 (PD-L1) Expression in 
Lung Cancer” of NCCN. First of all, a deep understand-
ing is needed of the differences between innate (with con-
stitutive oncogenic signaling inducing PD-L1 expression 
on tumor cells) and adaptive immune resistance (with 
T cell-induced PD-L1 upregulation) and of the interac-
tion distance measurements. Multispectral fluorescent 
IHC with a 6-plex panel was used to analyze the tumor 
microenvironment in patients with melanoma to predict 
successful TIL generation. CD8 to FoxP3 ratio resulted 
to be predictive of ability to culture autologous TILs [2]. 
Using the same assay, Immuneprofiling was found to cor-
relate to overall survival in NSCLC treated with conven-
tional therapies. Finally, a head and neck squamous cell 
carcinoma (HNSCC) patients cohort was analyzed. Since 
most of HNSCC samples are primary tumor the invasive 
margin was tested first. Results indicate that both CD8+ 
T cells infiltrate in the tumor component of the invasive 
margin and PD-L1 expression in the tumor predict dis-
ease recurrence. Before the routine clinical application, a 
few steps will need to be covered: (a) the automation of 
the staining procedure (b) the “whole” digital multiplexed 
slides and consistent integration with H&E based work-
flows and (c) the development and validation of orthog-
onal approaches (e.g. Nanostring, RNAseq or Mass 
Spectrometry).
In the Stockholm cohort, it has been explored the 
prognostic impact of the Immune profile in colon can-
cer patients Dukes B and C, randomized to surgery or 
surgery and adjuvant treatment. When comparing sur-
gery alone versus surgery and adjuvant treatment, the 
difference between Dukes B and C is significant, with 
better survival with surgery and adjuvant for Dukes B. 
Treatment does not seem to change the outcome. Four 
biomarkers were tested in the cohort: HLA-A*02, major 
histocompatibility complex (MHC) class I, HLA-G and 
CD8+ lymphocytes. HLA-A*02 is a common allele in 
the Scandinavian population, known as a negative prog-
nostic factor and more important than the expression of 
MHC class I for patients with epithelial ovarian cancer. 
Duke C patients with HLA-A*02 genotype randomized 
to surgery only had a worst outcome, but it was not the 
case for patients with other HLA-A genotype. Also, 
women with HLA-A*02 genotype with Dukes C treated 
by surgery had worst prognosis but could improve the 
prognosis if treated with adjuvant chemotherapy. MHC 
class I showed a paradox, with better survival in the 
“absent” MHC subgroup. HLA-G protein expression 
on tumor cells was found to be a significant marker in 
men. Also CD8+ cytotoxic T cells at the tumor micro-
environment was found to be a significant marker in 
men compared to women. Women seem to have a 
worst prognosis if they are HLA-A*02 independent 
of CD8+ infiltration status, while men seem to have a 
worst prognosis with low CD8+ infiltration independ-
ent of HLA-A genotype. Moreover, CD8+ infiltration 
resulted to be predictive for survival in the whole cohort 
and the absence of HLA-A*02 genotype to be predictive 
for good survival in the female subgroup compared to 
CD8+ .
Discussion and conclusion
Despite the steady progress and the evidence about the 
importance of Immunoscore, several questions remain 
open. The first unanswered questions are how to explain 
“hot” and “cold” immune infiltrated tumors and what 
are the mechanisms associated with TIL infiltration. A 
number of contributing systems have been proposed, as 
mutations driver, chromosomal instability, T cell prolif-
eration [20] or T-cell attraction [21, 22]. When examin-
ing the chromosomal instability, mutation patterns, and 
gene expression profiling in 270 microsatellite insta-
bility-high (MSI-H) and in microsatellite stable (MSS) 
patients, those with microsatellite instability-high (MSI-
H) showed multiple Frameshift mutations. Also, major 
histocompatibility complex (MHC) Class I and II seem 
to have predictable immunogenic frameshift mutations 
on different HLA molecules. The genetic analysis of mis-
sense and frameshift immunogenic mutations (epitopes) 
compared to nonsense (silent) mutations seem to indi-
cate the genetic evidence of immunoediting, owing to a 
decrement in frameshift immunogenic mutations in MSI 
patients compared to silent mutations and to less than 
expected number of missense immunogenic mutations in 
CRC patients, and particularly MSI patients compared to 
silent mutations. On the other hand, Immunoscore high 
patients have prolonged survival regardless of the MSI 
status [23].
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Numerous analyses of large patient cohorts identified 
specific patterns of immune activation associated with 
patient survival. We established these as the immune 
contexture, encompassing the type, functional orien-
tation, density and location of adaptive immune cells 
within distinct tumor regions. Based on the immune con-
texture, a standardized, powerful immune stratification 
system, the Immunoscore, was delineated. The immune 
contexture is characterized by immune signatures also 
observed in association with the broader phenomenon 
of immune-mediated, tissue-specific destruction. We 
defined these as the immunologic constant of rejection. 
Predictive, prognostic, and mechanistic immune signa-
tures overlap, and a continuum of intratumoral immune 
reactions exists. The balance between tumor cell growth 
and elimination may be tipped upon a crescendo induced 
by immune manipulations aimed at enhancing naturally 
occurring immunosurveillance. We propose a broader 
immunological interpretation of these three concepts—
immune contexture, Immunoscore, and immunologic 
constant of rejection—that segregates oncogenic pro-
cesses independently of their tissue origin. The immune 
contexture is defined as the type, functional orientation, 
density, and location of adaptive immune cells within 
distinct tumor regions. The Immunoscore is derived 
from three aspects of the immune contexture: the type, 
density, and location of immune cells. The functional 
orientation of the immune contexture is characterized 
by immune signatures qualitatively similar to those pre-
dicting response to immunotherapy, which are observ-
able in association with the broader phenomenon of 
immune-mediated, tissue-specific destruction. These 
signatures are detectable during regression of cancer fol-
lowing immunotherapy, allograft rejection, Graft versus 
Host Disease, flares of autoimmunity, or destruction of 
virally infected cells to clear intracellular pathogens. We 
defined them as the immunologic constant of rejection. 
Intratumoral immune biomarkers measure the status of 
activation of a naturally protective mechanism, which, 
if successfully elicited, will lead to tumor destruction. 
Thus, with a few exceptions, it is probable that predictive 
immune biomarkers will overlap with the prognostic and 
the mechanistic ones. Although the redundancy between 
prognostic, predictive, and mechanistic immune signa-
tures could seem obvious, the basis of its molecular con-
tinuum has only been recently proposed [24].
To well define Immunoscore in melanoma, it needs to 
evaluate additional cohort with the Immunoscore-in-
lymph-nodes algorithm and to verify the possibility of 
scoring the immuno-infiltrate in melanoma also analyz-
ing the functionality of the different immune cells. It will 
be important to evaluate the immuno-infiltrate in lymph 
nodes in a large cohort of patients and to correlate this 
with the outcome from adjuvant treatments, as well as to 
go further with the Immunoprofiling analysis (IDO, TIM-
3, CD137, etc.)
In conclusion, the next steps to promote the Immu-
noscore in routine clinical settings include the reinforce-
ment of the demonstration of its prognostic value, of 
its predictive value and the identification of the follow-
up parameters that could modify the initial prognostic 
power of the Immunoscore.
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